The Effect of Discharge Education on Recovery Quality and Self-Efficacy After Hysterectomy

April 21, 2026 updated by: Derya Yuksel KOÇAK, Hitit University

Impact of Orem-Based Discharge Education on Recovery Quality and Self-Efficacy After Hysterectomy: A Randomized Controlled Study

This randomized controlled trial investigated the effect of discharge education based on Orem's Self-Care Theory on postoperative recovery quality and self-efficacy in women undergoing hysterectomy. The study used a pretest/posttest control-group design and included 64 randomly selected women. The study sample consisted of two groups: an intervention group (n=32) and a control group (n=32). Data were collected between December 1, 2024, and May 31, 2025, from women who presented to the Obstetrics and Gynecology clinic of a training and research hospital in Çorum, Türkiye, and met the inclusion criteria. Data were obtained using the Patient Demographic Information Form, the Quality of Recovery-40 Scale, and the General Self-Efficacy Scale. Women in the intervention group received enhanced face-to-face discharge education based on the Orem Self-Care Theory before discharge, while the control group received standard face-to-face discharge education. Pre-test data were collected via self-report in a hospital setting, while post-test data were collected by telephone at the 4th postoperative week from the intervention group, with the researcher marking the questionnaire responses. The data were analyzed using SPSS version 26.0. Descriptive statistics, Pearson chi-square test, independent samples t-tests, paired samples t-tests, and Fisher's exact test were used in the analysis of the data.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

In this study, women undergoing hysterectomy surgery will be randomly assigned to two groups. The effects of routine, nurse-led, face-to-face discharge education will be compared with those of face-to-face discharge education based on OREM's self-care theory, focusing on quality of recovery and self-efficacy outcomes.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
64

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women who voluntarily agree to participate in the study
  • Women who have undergone hysterectomy
  • Conscious and able to respond to questions
  • Able to speak and understand Turkish
  • No communication problems
  • Literate with adequate reading comprehension
  • No cognitive impairment
  • No diagnosis of cancer

Exclusion Criteria:

  • Women with hearing or speech impairments
  • Women with cognitive impairment
  • Women who underwent emergency hysterectomy
  • Patients requiring intensive care in the postoperative period
  • Women who do not agree to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Education group
Discharge education based Orem's Self Care Theory
Other: Discharge education based on Orem's self care theory led by a nurse only one time, face-to-face
discharge education led by a nurse based Orem's Self Care Theory
Other Names:
  • discharge education
  • discharge training
No Intervention: Control Group
Routine Discharge education

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Self-Efficacy Scale
Time Frame: 4 weeks
Developed by Sherer et al. in 1982, the scale is used to assess patients' general self-efficacy. The original version of the scale, for which Turkish validity and reliability studies have been conducted, consisted of 23 items, while it was revised to 17 items by Yıldırım and İlhan (2010). The scale consists of five-point Likert-type questions (1. Never, 5. Very good). It comprises three sub-dimensions: initiation (2, 4, 5, 6, 7, 10, 11, 12, 17), perseverance (3, 13, 14, 15, 16), and persistence (1, 8, 9). The scoring ranges from 1 to 5, and questions 2, 4, 5, 6, 7, 10, 11, 12, 14, 16, and 17 are reverse-scored. The lowest possible score on the scale is 17, and the highest is 85. A high score on the scale indicates a high level of self-efficacy belief. In the validity and reliability study of the scale, the Cronbach's Alpha internal consistency coefficient was determined as 0.80 (Efendioğlu, 2024). In this study, the Cronbach's Alpha internal consistency coefficient was found to be 0.8
4 weeks
The Quality of Recovery-40 Questionnaire
Time Frame: 4 weeks
Developed by Myles and colleagues in 2000, this scale assesses the quality of recovery in patients. Its Turkish validity and reliability were established in 2014. The Quality of Recovery-40 Questionnaire consists of 40 items encompassing five sub-dimensions: Emotional State (9 questions), Physical Comfort (12 questions), Patient Support (7 questions), Physical Independence (5 questions), and Pain (7 questions). The Quality of Recovery-40 Questionnaire is divided into Part A and Part B. Part A addresses how the patient felt in the last 24 hours, and responses are requested for each item. Part B inquires about the presence of specific physical or emotional symptoms in the last 24 hours. Questions are evaluated using a 5-point Likert scale. The total score is obtained by summing all items. A score of 40 indicates "very poor quality of recovery," and a score of 200 indicates "excellent quality of recovery." The Cronbach's alpha coefficient of the Quality of Improvement-40 Questionnaire w
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hitit University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Erol Olcok Corum Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 12, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Ethics number 2024-GOAEK-0424
  • Master Thesis (Other Identifier: Hitit University)
  • Ethic committee aproval number (Other Identifier: Hitit University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Age, education level, marital status, income level, family type, partner's age and the other quantitative data

IPD Sharing Time Frame

01/ DEC/ 2026 "5 years after study completion

IPD Sharing Access Criteria

De-identified individual participant data (IPD) and supporting documents (study protocol and informed consent form) will be available to qualified researchers who submit a reasonable request. Access will be provided via secure email or institutional data-sharing platform after approval by the principal investigator. Data will include study variables related to post-hysterectomy recovery, self-care education, and self-efficacy outcomes. Personal identifiers will not be shared to ensure participant confidentiality.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings